Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

464 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Pediatric low-grade gliomas: next biologically driven steps.
Jones DTW, Kieran MW, Bouffet E, Alexandrescu S, Bandopadhayay P, Bornhorst M, Ellison D, Fangusaro J, Fisher MJ, Foreman N, Fouladi M, Hargrave D, Hawkins C, Jabado N, Massimino M, Mueller S, Perilongo G, Schouten van Meeteren AYN, Tabori U, Warren K, Waanders AJ, Walker D, Weiss W, Witt O, Wright K, Zhu Y, Bowers DC, Pfister SM, Packer RJ. Jones DTW, et al. Among authors: packer rj. Neuro Oncol. 2018 Jan 22;20(2):160-173. doi: 10.1093/neuonc/nox141. Neuro Oncol. 2018. PMID: 29016845 Free PMC article. Review.
Response assessment in paediatric low-grade glioma: recommendations from the Response Assessment in Pediatric Neuro-Oncology (RAPNO) working group.
Fangusaro J, Witt O, Hernáiz Driever P, Bag AK, de Blank P, Kadom N, Kilburn L, Lober RM, Robison NJ, Fisher MJ, Packer RJ, Young Poussaint T, Papusha L, Avula S, Brandes AA, Bouffet E, Bowers D, Artemov A, Chintagumpala M, Zurakowski D, van den Bent M, Bison B, Yeom KW, Taal W, Warren KE. Fangusaro J, et al. Among authors: packer rj. Lancet Oncol. 2020 Jun;21(6):e305-e316. doi: 10.1016/S1470-2045(20)30064-4. Lancet Oncol. 2020. PMID: 32502457 Review.
Neurofibromatosis Clinical Trial Consortium.
Packer RJ, Fisher MJ, Cutter G, Cole-Plourde K, Korf BR. Packer RJ, et al. J Child Neurol. 2018 Jan;33(1):82-91. doi: 10.1177/0883073817739196. J Child Neurol. 2018. PMID: 29246097 Review.
Selumetinib in paediatric patients with BRAF-aberrant or neurofibromatosis type 1-associated recurrent, refractory, or progressive low-grade glioma: a multicentre, phase 2 trial.
Fangusaro J, Onar-Thomas A, Young Poussaint T, Wu S, Ligon AH, Lindeman N, Banerjee A, Packer RJ, Kilburn LB, Goldman S, Pollack IF, Qaddoumi I, Jakacki RI, Fisher PG, Dhall G, Baxter P, Kreissman SG, Stewart CF, Jones DTW, Pfister SM, Vezina G, Stern JS, Panigrahy A, Patay Z, Tamrazi B, Jones JY, Haque SS, Enterline DS, Cha S, Fisher MJ, Doyle LA, Smith M, Dunkel IJ, Fouladi M. Fangusaro J, et al. Among authors: packer rj. Lancet Oncol. 2019 Jul;20(7):1011-1022. doi: 10.1016/S1470-2045(19)30277-3. Epub 2019 May 28. Lancet Oncol. 2019. PMID: 31151904 Free PMC article. Clinical Trial.
Reproducibility of cognitive endpoints in clinical trials: lessons from neurofibromatosis type 1.
Payne JM, Hearps SJC, Walsh KS, Paltin I, Barton B, Ullrich NJ, Haebich KM, Coghill D, Gioia GA, Cantor A, Cutter G, Tonsgard JH, Viskochil D, Rey-Casserly C, Schorry EK, Ackerson JD, Klesse L, Fisher MJ, Gutmann DH, Rosser T, Packer RJ, Korf B, Acosta MT, North KN; NF Clinical Trials Consortium. Payne JM, et al. Among authors: packer rj. Ann Clin Transl Neurol. 2019 Dec;6(12):2555-2565. doi: 10.1002/acn3.50952. Epub 2019 Dec 3. Ann Clin Transl Neurol. 2019. PMID: 31797581 Free PMC article. Clinical Trial.
Impact of MEK Inhibitor Therapy on Neurocognitive Functioning in NF1.
Walsh KS, Wolters PL, Widemann BC, Del Castillo A, Sady MD, Inker T, Roderick MC, Martin S, Toledo-Tamula MA, Struemph K, Paltin I, Collier V, Mullin K, Fisher MJ, Packer RJ. Walsh KS, et al. Among authors: packer rj. Neurol Genet. 2021 Aug 6;7(5):e616. doi: 10.1212/NXG.0000000000000616. eCollection 2021 Oct. Neurol Genet. 2021. PMID: 34377779 Free PMC article.
Visual spatial learning outcomes for clinical trials in neurofibromatosis type 1.
Ullrich NJ, Payne JM, Walsh KS, Cutter G, Packer R, North K, Rey-Casserly C; NF Clinical Trials Consortium. Ullrich NJ, et al. Ann Clin Transl Neurol. 2020 Feb;7(2):245-249. doi: 10.1002/acn3.50976. Epub 2020 Feb 5. Ann Clin Transl Neurol. 2020. PMID: 32022434 Free PMC article. Clinical Trial.
464 results